Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acitretin 30 mg and CSF APPsα levels in mild to moderate Alzheimer's disease
2009-011881-27Phase 2Completed
- Sponsor
- University Medical Center Mainz
- Start
- Jan 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Alzheimer's disease (AD) comparing Acitretin 30 mg daily with Placebo (2 arms). Primary endpoint: Change in CSF APPsα concentration. Started Jan 2010; status: completed.
02
Drugs
acitretin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2009-011881-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011881-27.